Pharma BD Deal Intelligence

AstraZeneca plc / Pfizer Inc.

2016 · Asset Purchase · $1.6B · Complete

Announcement Sentiment

Strongly positive

AstraZeneca sold its small molecule antibiotics business to Pfizer for up to $1.575B: $550M upfront cash, $175M deferred (paid January 2019), up to $250M in milestone payments, plus up to $600M in sales-related payments and tiered royalties on Zavicefta and ATM-AVI. Portfolio: marketed Zavicefta, Merrem, Zinforo plus clinical-stage ATM-AVI and CXL. Completed December 2016.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Aug 22, 2016
Closed Dec 23, 2016
Deal value $1.6B
Deal type Asset Purchase
Therapeutic area Multidrug-resistant Gram-negative and other serious bacterial infections
Indications Multidrug-resistant Gram-negative and other serious bacterial infections
Key assets Zavicefta (ceftazidime-avibactam); Merrem/Meronem (meropenem); Zinforo (ceftaroline); aztreonam-avibactam (ATM-AVI); CXL
Mechanism Beta-lactam antibiotics and beta-lactamase inhibitor combinations

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals